SAN GIEGO, CA Irena Steele, Senior Research Scientist, at Memorial Sloan-Kettering Cancer Center, to speak at GTCbio’s 5th Assay and Drug Discovery Technologies on Sept. 20-21, 2010 in San Diego, CA.
Irena Steele will give a presentation on “A High content screening approach for the ABCG2 transporter: Merits of live cell assays.” at 5th Assay and Drug Discovery Technologies Conference to be held this year in San Diego, CA Sept. 20-21, 2010 by GTCbio. Her group has developed a live cell based assay to screen for modulators of the ABCG2 transporter using an isogenic pair of U87 cell lines with one cell line over expressing the transporter and used for screening and the other line used to assess fluorescence enhancement accumulation due to the physico chemical properties of identified modulators and to eliminate them as auto-fluorescent compounds. She will present her findings and discuss the potential application of this approach for the elucidation of the ABCG2 function and regulation.
Irena Steele received her PhD in Developmental Toxicology and Embryology from Tel Aviv University, Israel in 1999. She completed her postdoctoral fellowship at University of New Mexico, where her research concentrated on the effects of environmental agents on angiogenesis and heart development. In 2006 Irena started to work at Center for Molecular Discovery, where she was specializing in cancer related research with application to the drug discovery technologies. Working at New Mexico Center for Molecular Discovery she was developing HTS assays using flow cytometry. Currently Irena is working as a Senior Research Scientist at MSKCC’s HTS Core Facility where she is using her expertise in cell-based assay development and high-content screening.
Also presenting at the Assay and Drug Discovery Technologies are prestigious organizations including Burnham Medical Research Institute, Pfizer, UCSF, AstraZeneca, UCLA, Bristol Myers Squibb, Genentech, National Institute of Advanced Science and Technology, Johnson & Johnson, Nexigen GmbH, University of Pennsylvania, Roche, UCD, Abbott, Merck, Novartis (GNF), and other leaders in the Assay and Drug Discovery Technologies industry.
5th Assay and Drug Discovery Technologies Conference features a mixture of academic, industry and public sector experts in an intimate setting that favors the showcase of data, the exchanges of ideas and networking. Professionals in the drug discovery industry and academics to can get an update of exciting new developments in assay technologies and exchange ideas in developing creative approaches in the drug discovery and development process to improve the efficiency and output. For more information, visit www.gtcbio.com.
Last updated on: 27/08/2010